Drug intelligence / Profile preview

DHP-101

Development stage: Unknown
Lead developer: Optus
Modality: Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Ophthalmic

Overview

DHP-101 is a pharmaceutical drug developed by OPTUS Pharmaceutical Co., Ltd. It has been investigated for the treatment of eye diseases, specifically Dry Eye Syndrome. A Phase 2 clinical trial (NCT00788229) evaluating its efficacy and safety in patients with Dry Eye Syndrome has been completed. The specific mechanism of action and modality of DHP-101 are not publicly detailed in the available information.

Other names: sodium hyaluronate + carboxymethylcellulose sodium eye drops

Targets

CD44 (CD44 antigen)

Beyond the preview

Go deeper on DHP-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DHP-101.

Explore the full profile